ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,436.20
-0.10%
S&P ASX All Technology
3,964.00
0.35%
Brent Oil
72.33
-0.47%
US Dollar vs AUD
1.53293
-0.25%
Bitcoin
97,297.09
1.71%
Pepperstone
Advertisement
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. XTL Biopharmaceuticals Ltd (XTLB)

  7. XTL Biopharmaceuticals Ltd (XTLB) News

XTLB

XTL Biopharmaceuticals (XTLB)

XTL Biopharmaceuticals Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:XTLB
DateTimeSourceHeadlineSymbolCompany
20/11/202409:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/11/202401:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/10/202400:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/08/202423:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/08/202423:15GlobeNewswire Inc.XTL Completed the Acquisition of The Social Proxy and a Private Placement of $1.5 MillionNASDAQ:XTLBXTL Biopharmaceuticals Ltd
23/07/202406:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
13/06/202406:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202423:20Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
05/06/202423:15GlobeNewswire Inc.XTL Entered Definitive Agreement to Acquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
14/05/202400:32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
21/03/202401:15GlobeNewswire Inc.XTL To Aquire The Social ProxyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
16/11/202302:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
21/10/202307:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
21/10/202307:00GlobeNewswire Inc.XTL Biopharmaceuticals Confirms that it has not Experienced any Disruption to its Business Operations in IsraelNASDAQ:XTLBXTL Biopharmaceuticals Ltd
21/10/202307:00GlobeNewswire Inc.XTL Biopharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyNASDAQ:XTLBXTL Biopharmaceuticals Ltd
10/08/202323:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:XTLBXTL Biopharmaceuticals Ltd
17/05/202301:01Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
24/02/202306:30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
02/02/202301:53Edgar (US Regulatory)Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
25/08/202200:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
31/03/202208:16Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
27/01/202204:43Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/01/202203:04Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
17/12/202109:17Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
25/11/202102:39Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/06/202120:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/05/202101:40Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/05/202101:31Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
20/05/202101:26Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
08/01/202101:10Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:XTLBXTL Biopharmaceuticals Ltd
 Showing the most relevant articles for your search:NASDAQ:XTLB

Your Recent History

BIT
UC837C
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36